KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $41.0 million.

  • Nektar Therapeutics' Cash & Equivalents rose 36.28% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 36.28%. This contributed to the annual value of $44.3 million for FY2024, which is 25.44% up from last year.
  • Nektar Therapeutics' Cash & Equivalents amounted to $41.0 million in Q3 2025, which was down 4.55% from $43.0 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Cash & Equivalents high stood at $152.3 million for Q2 2021, and its period low was $25.2 million during Q4 2021.
  • Its 3-year average for Cash & Equivalents is $45.6 million, with a median of $43.0 million in 2025.
  • In the last 5 years, Nektar Therapeutics' Cash & Equivalents tumbled by 87.32% in 2021 and then spiked by 249.86% in 2022.
  • Over the past 5 years, Nektar Therapeutics' Cash & Equivalents (Quarterly) stood at $25.2 million in 2021, then soared by 249.86% to $88.2 million in 2022, then plummeted by 60.02% to $35.3 million in 2023, then climbed by 25.44% to $44.3 million in 2024, then surged by 36.28% to $41.0 million in 2025.
  • Its Cash & Equivalents was $41.0 million in Q3 2025, compared to $43.0 million in Q2 2025 and $38.9 million in Q1 2025.